USHealthcare

Zimmer Biomet Holdings Inc (ZBH)

US · Healthcare · Medical Devices

$95.81-1.21%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.09B
Revenue YoY
+9.3%
Net profit
$238.1M
Profit YoY
+30.8%
EPS
$2.09
EPS estimate
$1.86
Net margin
11.4%

EPS came in at 2.09 against a street estimate of 1.86 — a beat of 12.4%.

Key statistics

Market cap
$18.17B
P/E
24.3
Forward P/E
11.2
P/B
1.43
Book value
$65.53
EPS (TTM)
$3.86
Dividend yield
1.01%
52-week high
$107.16
52-week low
$78.91
50-day MA
$88.71
200-day MA
$91.11
Beta
0.46

Analyst view

Analysts rate Zimmer Biomet Holdings Inc a hold (11 buy, 16 hold, 2 sell out of 29) with an average price target of $99.38.

Shareholding

Insiders
0.15%
Institutions
106.28%

Largest institutional holders

FundStake
Dodge & Cox12.17%
BlackRock Inc7.93%
Harris Associates L.P.6.70%
Vanguard Capital Management, LLC6.61%
Capital Research & Mgmt Co - Division 34.71%
State Street Corp4.56%
Vanguard Portfolio Management, LLC4.47%
T. Rowe Price Associates, Inc.4.13%

Recent filings & reports

DocumentDate
Material agreement · Q2 20262026-06-29
Shareholder vote results · Q2 20262026-05-27
Reg FD disclosure · Q2 20262026-05-12
Quarterly report · Q1 20262026-05-01
Board / officer change · Q2 20262026-04-28
Proxy statement · Q2 20262026-04-01
Annual report FY20252026-02-20
Quarterly report · Q3 20252025-11-05

Readable in the app.

Deals & corporate news

AnnouncementDate
Increases share repurchase expectations to $1 billion by year end
Zimmer Biomet announced it is increasing its share repurchase program by $250 million, now expecting to buy back up to $1 billion of its own stock during fiscal year 2026. This increase come
2026-05-12
Q1 2026 results; raises full-year adjusted EPS and free cash flow guidance
Zimmer Biomet, a medical device company, reported strong first quarter 2026 results. Net sales reached $2.087 billion, up 9.3% year-over-year (6.8% excluding currency effects, 2.9% organic g
2026-04-28
Board approves new $1.5 billion stock repurchase authorization
Zimmer Biomet, a medical device company, reported 2025 results showing mixed performance. Revenue grew 7.2% to $8.232 billion, though organic growth was modest at 3.9%. Fourth quarter sales
2026-02-10
Announced definitive agreement to acquire Monogram Technologies
Zimmer Biomet reported strong Q2 2025 results with net sales of $2.077 billion, up 7.0% year-over-year (5.4% in constant currency, 2.8% organically). Adjusted earnings per share increased 3.
2025-08-07

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Zimmer Biomet Holdings Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-08-05.